Research ArticleOriginal Article
Open Access

Assessment of histopathological alterations in patients with chronic hepatitis B infection following long-term oral antiviral therapy

Ahmet Şahin, Mustafa Namıduru, Ayhan Balkan, İlkay Karaoğlan and Murat T. Gülşen
Saudi Medical Journal October 2018, 39 (10) 999-1005; DOI: https://doi.org/10.15537/smj.2018.10.23056

References

  1. ↵
    1. European Association for the Study of the Liver
    (2012) EASL clinical practice guidelines: management of chronic hepatitis. J Hepatol 57:167–185.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Akarca US
    (2008) Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow-up 2007. Turkish Association for the Study of Liver. Turk J Gastroenterol 19:207–230.
    OpenUrlPubMed
  3. ↵
    1. Tang CM,
    2. Yau TO,
    3. Yu J
    (2014) Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World J Gastroenterol 20:6262–6278.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Lok AS,
    2. McMahon BJ
    (2009) Chronic hepatitis B: update 2009. AASLD Clinical Guidelines. Hepatology 50:661–662.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Chang TT,
    2. Liaw YF,
    3. Wu SS,
    4. Schiff E,
    5. Han KH,
    6. Lai CL,
    7. et al.
    (2010) Long Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B. Hepatology 52:886–893.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Wu CY,
    2. Lin JT,
    3. Ho HJ,
    4. Su CW,
    5. Lee TY,
    6. et al.
    (2014) Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: A nationwide cohort study. Gastroenterology 147:143–151.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Keeffe EB,
    2. Dieterich DT,
    3. Han SH,
    4. Jacobson IM,
    5. Martin P,
    6. Schiff ER,
    7. et al.
    (2008) A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol 6:1315–1341.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Osamu Y,
    2. Koichi T,
    3. Shinichi F,
    4. Michiko S,
    5. Kazuaki C,
    6. Haruhiko K,
    7. et al.
    (2010) Long term use of entecavir in nucleoside naive Japanese patients with chronic hepatitis B infection. J Hepatol 52:791–799.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Chen CJ,
    2. Yang HI,
    3. Su J,
    4. Jen CL,
    5. You SL,
    6. Lu SN,
    7. et al.
    (2006) Risk of hepatocellüler carsinoma across a biyological gradient of serum hepatitis B virus DNA level. JAMA 295:65–73.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Liaw YF,
    2. Sung JJ,
    3. Chow WC,
    4. Farrell G,
    5. Lee CZ,
    6. Yuen H,
    7. et al.
    (2004) Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Eng J Med 351:1521–1531.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Chang TT,
    2. Gish RG,
    3. de Man R,
    4. Gadano A,
    5. Sollano J,
    6. Chao YC,
    7. et al.
    (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001–1010.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Yu MW,
    2. Yeh SH,
    3. Chen PJ,
    4. Liaw YF,
    5. Lin CL,
    6. Liu CJ,
    7. et al.
    (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 97:265–272.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. George VP,
    2. Spilios M,
    3. Athanasios JA
    (2008) Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 14:6902–6910.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Lok AS,
    2. McMahon BJ
    (2007) Chronic hepatitis B. Hepatology 45:507–539.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Fung SK,
    2. Wong F,
    3. Hussain M,
    4. Lok AS
    (2004) Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepatitis 11:432–438.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Xu Y,
    2. Zhang YG,
    3. Qi WQ,
    4. Wang X,
    5. Qin SY,
    6. Liu ZH,
    7. et al.
    (2015) Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol 21:7869–7876.
    OpenUrl
  17. ↵
    1. Guangbi Y,
    2. Cheng WC,
    3. Weilun L,
    4. Hong R,
    5. Deming T,
    6. Yuming W,
    7. et al.
    (2008) Virologic, serologic, and biochemical outcomes through 2 years of treatment with Entecavir and Lamivudine in nucleoside - naive Chinese patients with chronic hepatitis B: a randomized, multicenter study. Hepatol Int 2:486–493.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Shouval D,
    2. Akarca US,
    3. Hatkjs G,
    4. Kitis G,
    5. Lai CL,
    6. Cheniquer H,
    7. et al.
    (2006) Continued virologic and biochemical improvement through 96 week of entecavir treatment in HBeAg(-) chronic hepatitis B patients. J Hepatol 44:21.
    OpenUrl
  19. ↵
    1. Marcellin P,
    2. Gane E,
    3. Buti M,
    4. Afdhal N,
    5. Sievert W,
    6. Jacobson IM,
    7. et al.
    (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381:468–475.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Marcellin P,
    2. Asselah T
    (2013) Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 28:912–923.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Lai CL,
    2. Shouval D,
    3. Lok AS,
    4. Chang TT,
    5. Cheinquer H,
    6. Goodman Z,
    7. et al.
    (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011–1020.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. Leung NWY,
    2. Lai CL,
    3. Chang TT,
    4. Guan R,
    5. Lee CM,
    6. NG KY,
    7. et al.
    (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology 33:1527–1532.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Takehara T,
    2. Hayashi N,
    3. Takaguchi K,
    4. Yokosuka O,
    5. Fujioka S,
    6. Shindo M,
    7. et al.
    (2008) Efficacy and safety of 3 years treatment with entecavir in Japanese nucleoside-naive patients with chronic hepatitis B. Hepatology Int 2:97–98.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section